CHEK1, TOP2A, and c-MET as potential biomarkers for companion diagnostic development in triple-negative breast cancer
Journal of Advanced Biotechnology and Experimental Therapeutics · 2027 · 10 (1) · 1
DOI: 10.5455/jabet.2027.01 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Advanced Biotechnology and Experimental Therapeutics, 2027. Verfasst von Mohitha Sandrasagran und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Breast cancer is the most diagnosed cancer among women worldwide and represents a major global health burden due to its biological heterogeneity and variable clinical outcomes. Triple-negative breast cancer (TNBC) is a clinically aggressive subtype characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. Molecularly heterogeneous and lacking targeted treatments, TNBC is associated with poor outcomes and high recurrence. This review evaluates the potential of CHEK1, TOP2A, and c-MET as biomarkers for companion diagnostics in TNBC. CHEK1 promotes DNA damage response and cell-cycle checkpoints, especially in p53-deficient tumours, and could serve as a predictive biomarker of sensitivity to CHEK1 inhibitors. TOP2A, which is involved in DNA replication and chromosomal segregation, is frequently overexpressed in highly proliferative TNBC and correlates with response to anthracycline-based chemotherapy. c-MET, a receptor tyrosine kinase, drives tumour progression, invasion, and therapeutic resistance; its overexpression is associated with poor clinical outcomes and has been linked to emerging targeted therapies. Collectively, CHEK1, TOP2A, and c-MET represent promising biomarkers for Companion diagnostic development in TNBC. However, further analytical validation, prospective clinical validation, and assay standardization efforts are needed prior to clinical use.
Zitieren
APA
Sandrasagran, M., Sachit, B., & Balakrishnan, V. (2027). CHEK1, TOP2A, and c-MET as potential biomarkers for companion diagnostic development in triple-negative breast cancer. Journal of Advanced Biotechnology and Experimental Therapeutics, 10(1), 1. https://doi.org/10.5455/jabet.2027.01
Vancouver
Sandrasagran M, Sachit B, Balakrishnan V. CHEK1, TOP2A, and c-MET as potential biomarkers for companion diagnostic development in triple-negative breast cancer. Journal of Advanced Biotechnology and Experimental Therapeutics. 2027;10(1):1. doi:10.5455/jabet.2027.01
BibTeX
@article{Sandrasagran2027,
author = {Sandrasagran, Mohitha and Sachit, Bassam and Balakrishnan, Venugopal},
title = {CHEK1, TOP2A, and c-MET as potential biomarkers for companion diagnostic development in triple-negative breast cancer},
journal = {Journal of Advanced Biotechnology and Experimental Therapeutics},
year = {2027},
volume = {10},
number = {1},
pages = {1},
doi = {10.5455/jabet.2027.01}
}
EUVIMED